Index

Addiction: **Lingford-Hughes AR, Davies SJC, McIver S, Williams TM, Daglish MRC, Nutt DJ**, 209–222
Advanced brain imaging procedures and human memory disorder: **Kapur N & Kopelman MD**, 61–81
Ageing and dementia, 159–168
AIDS-dementia complex, executive deficits and, 50
Alcohol and psycho-active substance misuse, 65, 209–222
Alzheimer's disease and
  activated microglia, 128, 129
  apolipoprotein E (APOE) genotype, 164, 166
  CNS inflammation, 247
  executive deficits, 50, 65, 67, 69, 71
  imaging techniques, 159–168
Amygdala and 5-HTT, 266–267
Animal models of brain disease neuroimaging of, 235–257
Aphasic patients, 110–116
Apolipoprotein E (APOE) gene, 69
  and Alzheimer's disease (AD), 164, 166
    late-onset familial AD, 262, 264–265, 266
Apparent diffusion coefficient (ADC) and, 147, 151
  ischaemic injury, 235
  epilepsy models, 241
  traumatic brain injury, 242, 247, 248
Arterial spin labelling (ASL), 147, 148
Ascending reticular activating system (ARAS), 22–23
Attention and its disorders: **Gitelman DR**, 21–34
  anatomical and behavioural models, 24–28
  attention components, 22–24
  confusional states, 28–30
  definition, 22
  domain-specific/'partial' impairments, 30
  hemispatial neglect, 30–32
  partial attentional syndromes, 30

Banati RB: Neuropathological imaging: *in vivo* detection of glial activation as a measure of disease and adaptive change in the brain, 121–131

Baron JC *see* **Guadagno JV**
Blood oxygenation level-dependent (BOLD) mechanism in functional MRI (BOLD-fMRI), 140, 145
  and migraine, 224
  and epilepsy, animal models of, 240
Brain-based algorithms for diagnosis and optimised treatment of depression, 193–207
Brain damage and aphasia, 95–119
Brain tumours, 63

Calautti C *see* **Guadagno JV**
Capsaicin, 84
Catechol-*o*-methyltransferase (COMT) gene and prefrontal dopamine neurotransmission, 262, 265
Caudate strokes and depression, 196
Central nervous system (acute) inflammation, animal models, 246–249
Cerebral blood flow (CBF)
  and headaches, 223–234
  and ischaemic injury, 235
  relative, 147–149, 151, 153
  regional, 23
Cerebral blood volume (CBV), 247, 248
Cerebral ischaemia, animal models, 235–239
Cerebral metabolic rate of oxygen consumption ($CMRO_2$) and ischaemic injury, 237
Cerebral perfusion pressure (CPP), 149
Choline-containing phospholipids (Cho), proton MRS , 139–140, 184–185
Cocaine abuse, 209–222
Cognitive tasks and motor, fMRI of, 179
Communication in man and animals, 95–119
Confusional states, 28–30
Conventional MRI (cMRI) see Magnetic resonance imaging
Cortical contusion injury (CCI), animal model, 243
Cortical map changes and network re-organisation, after stroke, 154–156
Cortical spreading depression (CSD), 224
Creatine and phosphocreatine (Cr), proton MRS, 139–140, 184

DOI 10.1093/bmb/ldg65.271
© The British Council 2002

Creutzfeldt-Jakob disease, 63
prion disease and CNS inflammation, 247
Critchley HD: Emotion and its disorders, 35–47

Daglish MRC *see* **Lingford-Hughes AR**
Davies SJC *see* **Lingford-Hughes AR**
Dementia, 63, 64, 69, 71–74
Dementia and ageing: **Good CD**, 159–168
Depression
executive deficits and, 50
modulating dysfunctional limbic-cortical circuits in, 193–207
Derbyshire SWG *see* **Jones AKP**
Diffusion and perfusion MRI, 66–67
Diffusion-weighted (DW) MR imaging (DWI), 66–67, 133, 136–139, 145–147, 150–152, 186
and epilepsy, 241
and ischaemic inhury, 238–239
Diffusion tensor imaging (DTI), 145, 147, 156, 185–186
and depression, 210
Dorsolateral prefrontal cortex (DLPFC), 52–54
Drug development, neuropharmacology and, 169–177
Dynamic susceptibility contrast (DSC) MRI, 147

Electrical stimulation mapping (ESM), 188–190
Ekectro-encephalogram (EEG)
frequency analysis, 84
neuropharmacology, 169
surgical mapping, 187
video-EEG telemetry, 182
Electrophysiological techniques, 83–93, 145, 155–156
Eloquent cortex, imaging of, 179, 180, 186, 187–190
Emotion and its disorders: **Critchley HD**, 35–47
processing of emotional cues, 35–39
representation of internal feeling states, 39–42
emotional and motivational learning, 42–44
Epilepsy and surgical mapping: **Richardson MP**, 179–192
Epilepsy, animal models, 239–241
Epileptogenic zone, imaging of, 180–182
Event-related potentials (ERP), 71
Executive functions and their disorders: **Elliott R**, 49–59
neuroimaging of, 55–57
Experimental allergic encephalopathy (EAE), 245–246

Filippi M *see* **Rovaris M**
Fluid attenuated inversion recovery (FLAIR) sequences, 63
Fractional anisotropy (FA), 135, 136–138
Functional magnetic resonance imaging (fMRI), 3–10, 67–71, 84–85, ubiquitous
and addiction, 209-222
ageing and dementia, 159–168
attention and its disorders, 21, 31, 32
basic mechanism, 3–5
blood oxygenation level-dependent (BOLD-fMRI), 145, 146
data acquisition, 6
data analysis, 8–9
equipment, 5–6
and headaches, 223–234
and language systems in normal and aphasic human subjects, 95–119
limitations, 9
motor and cognitive tasks, 179–192
and multiple sclerosis (MS), 140-141
potential, 9–10
sources of error, 7–8
study of pain, scope and limitations of, 84–87
task presentation, 6
types of experiment, 7
Functional polymorphisms, 262

Gee A: Neuropharmacology and drug development, 169–177
Genomics, imaging, 259–270
Gitelman DR: Attention and its disorders, 21–34
Glial activation (detection *in vivo*) as a measure of disease and adaptive change in the brain, 121–131
Good CD: Dementia and ageing, 159–168
Guadagno JV, Calautti C & Baron JC: Progress in imaging stroke: emerging clinical applications, 145–157

Hariri AR & Weinberger DR: Imaging genomics, 259–270
Harris NG *see* **Lythgoe MF**
Headache – lessons learned from functional imaging: **May A**, 223–234
  cluster, 226–229
  experimental, 229–230
  vascular, 230–231
Hemispatial neglect, 30–32
Herpes encephalitis, 64
  and activated microglia, 128, 129
Hippocampal
  lesions in hypoglycaemia, 63
  sclerosis (HS), 180–190
HIV-related dementia and CNS inflammation, 247
5-HTT gene, 262
Huntington's disease
  animal model, 244
  and depression, 196
  executive function impairment and, 51
  trans-synaptic 'knock-on' effects, 125

Imaging genomics: Hariri AR & Weinberger DR, 259–270
Imaging neuroscience, techniques for, 3–20
  fMRI, 3–10
  PET, 10–18
Internal feeling states, representation of, 39–42
Intra-operative hippocampal electro-corticography, 72
Introduction: **Frackowiak RSJ & Jones T**, 1–2
Ischaemic (subcortical) vascular disease, executive deficits and, 50

Jamesian model of emotional processing, 37
Jones AKP, Kulkarni B & Derbyshire SWG: Pain mechanisms and their disorders, 83–93
Jones T *see* **Frackowiak RSJ, Turner R**

Kapur N & Kopelman MD: Advanced brain imaging procedures and human memory disorders: 61–81
Kopelman MD *see* **Kapur N**
Kulkarni B *see* **Jones AKP**

Lactate (Lac), methyl resonance of, proton MRS for MS, 139–140
Language systems in normal and aphasic human subjects: functional imaging studies and inferences from animal studies: **Wise RJS**, 95–119
Limbic-cortical circuits in depression, modulating dysfunctional, 193–207
Lingford-Hughes AR, Davies SJC, McIver S, Williams TM, Daglish MRC, Nutt DJ: Addiction, 209–222
Lythgoe MF, Sibson NR & Harris NG: Neuroimaging of animal models of brain disease, 235–257

Magnetic resonance angiography (MRA), 145
Magnetic resonance-based techniques for the study and management of multiple sclerosis: **Rovaris M, Rocca MA & Filippi M**, 33–144
Magnetic resonance imaging (MRI), 62–63
  see also Functional (fMRI)
  ageing and dementia, 159–168
  conventional, 133–136
  diffusion-weighted (DW), 133, 136–139
  magnetization transfer (MT), 133, 136–139
  and neuropharmacology, 169, 174
  for stoke patients, 145–157
Magnetic resonance spectroscopy (MRS), 66–66, 165
Magnetization transfer (MT) imaging, 133, 136–139, 165
Magnetization transfer ratio (MTR), 136–139
Magneto-encephalography (MEG), 71, 84–85, 145
Mapping of
  brain electrical and magnetic activity, 71
  (surgical) for epilepsy treatmnt, 179–192
May A: Headache – lessons learned from functional imaging, 223–234
Mayberg HS: Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment, 193–207
McIver S *see* Lingford-Hughes AR
Mean transit time (MTT), 147, 146, 148, 150, 151

Memory disorders (human): advanced brain imaging procedures and, 61–81
Metabolic (remote) effects of stroke, 154
Methamphetamine abuse, 209–222
Microglia activation detected by PET, 121–131
Middle cerebral artery (MCA), 148, 151–152, 154
and ischaemic injury, 235
velocity and headache, 225
Migraines, 224–226
5-HT1a agonists, 83
Mini mental state examination (MMSE), 165
Model of
emotional processing, Jamesian, 37
attention and its disorders anatomical and behavioural, 24–28
Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment: **Mayberg HS**, 193–207
Motivational and emotional learning, 42–44
Motor and cognitive tasks, fMRI of, 179
Multiple sclerosis, 63, 65
animal model, 244
and activated microglia, 128, 129
magnetic resonance-based techniques for the study and management of, 133–144
Multiple systems atrophy, executive function and impairment, 50

N-acetylaspartate (NAA), 64, 65, 139–141
and dementia, 165
epilepsy, 184–185
fMRI, 140–141, 184–185
proton MRS, 139–140, 184–185
Near-infrared spectroscopy, 72
Neuro-anatomical changes in
ageing, 161–162
dementia, 162–164
Neurobehavioural disorders, 193–207
Neurochemical functional brain imaging, 72
Neuroimaging of animal models of brain disease: Lythgoe MF, Sibson NR & Harris NG, 235–257
Neuropathological imaging: *in vivo* detection of glial activation as a measure of disease and adaptive change in the brain: **Banati RB**, 121–131
Neuropharmacology and drug development: **Gee AD**, 169–177
Nociceptive processing, acute and chronic, 83–93
Normal-appearing white matter (NAWM), 136–141
Novel ways of representing resting oxygen levels using MR imaging, 72
Nuclear magnetic resonance (NMR)
for stroke or cerebral ischaemia, 235
animal model of epilepsy, 240
Nutt DJ *see* **Lingford-Hughes AR**

Opiates abuse, 209–222
Optical imaging, 72
Oxygen extraction fraction (OEF) and ischaemic injury, 237–238

Parkinson's disease
animal model, 244
and depression, 196
executive function impairment and, 50, 56
MPTP-induced, and activated microglia, 125, 129
Pain-evoked potentials, 84–85
Pain matrix, 86
Pain mechanisms and their disorders: **Jones AKP, Kulkarni B & Derbyshire SWG**, 83–93
Pain, psychogenic and neuropathic, 83–93
Paralimbic hypometabolism and depression, 196
PET using [^{11}C]-(R)-PK11195 binding to microglia, 127–129
Positron emission tomography (PET), 10–18, 67–71, ubiquitous
Alzheimer's and ([^{11}C]-(R)-PK11195), 165
microglia and ([^{11}C]-(R)-PK11195), 127–129
basic mechanism, 10–12
data acquisition, 13–14
and depression, 196–197
detection of neuropathology, 121–131
[^{18}F]-fluorodeoxyglucose (FDG), 84–85
equipment, 12–13
data analysis, 16–17
language systems in normal and aphasic human subjects, 95–119
limitations, 17–18
and neuropharmacology, 169–177
potential, 18

sources of error, 15–16
and stroke, 148–150, 152, 156
task presentation, 14
types of experiment, 14–15
Perfusion-weighted MR imaging (PWI), 66–67, 145, 147–148, 150–152
Peripheral benzodiazepine binding site (PBBS), PK11195 binds to, 127–129
PK11195 (isoquinoline) binds to the peripheral benzodiazepine binding site (PBBS), 127–129
Post mortem imaging and quantitative analyses of brain tissue, 72
Primary motor cortex (M1), 155–156
Primary progressive (PP) form of MS, 134, 141
Prion disease, 64
and CNS inflammation, 247
Progressive supranuclear palsy, executive function impairment and, 60
Progress in imaging stroke: emerging clinical applications: Guadagno JV, Calautti C & Baron JC, 145–157
Proton MRS and MS, 139–140
Psycho-active substance and alcohol, misuse 209–222

Region of interest (ROI) approaches, brain structures by MRI , 160, 162
Regional cerebral blood flow (rCBF), 23
Relapsing-remitting multiple sclerosis (RRMS), 138, 140, 141
Richardson MP: Epilepsy and surgical mapping, 179–192
Rocca MA *see* **Rovaris M •**
Rovaris M, Rocca MA & Filippi M: Magnetic resonance-based techniques for the study and management of multiple sclerosis, 33–144

Schizophrenia, executive deficits and, 50, 56
Secondary progressive multiple sclerosis (SPMS), 136–139
Serotonin transporter gene (5-HTTLPR). 266–267
Sibson NR *see* **Lythgoe MF**
Single nucleotide polymorphisms (SNPs), 262
Single photon emission tomography (SPECT), 67–71
ageing and dementia, 164
in acute stroke, 150, 154
and depression, 196–197
and epilepsy, 184
and migraine, 224
and neuropharmacology, 169
Speech and brain activity, 95-119
Spreading depression (SD) emanating from an infarct core, 238–239
Statistical parametric mapping (SPM), 180, 189
Striatal dopamine transporter (DAT), 212, 214–215
Stroke
activated microglia, 128, 129
animal models. 235–239
CNS inflammation, 247
-induced aphasia, 95–119
mapping and epilepsy, 179–192
progress in imaging, 145–157
Subarachnoid haemorrhage (SAH), 237
Surgical mapping and epilepsy, 179–192

T_2 mapping, 66
Techniques for imaging neuroscience: **Turner R & Jones T**, 3–20
Temporal lobe epilepsy (TLE), 64–66,68–69,72,179,180,190
Time-to-peak (TTP), 147
Tractography, 186
Transcranial magnetic stimulation (TMS), 72, 145, 155, 156
Transcranial Doppler ultrasonography, 72
Transient global amnesia (TGA), 67, 69
Trans-synaptic 'knock-on' effects for lesions in the visual system and in experimental lesion models of Huntington's disease, 125
Traumatic brain injury (TBI),
animal models, 241–243
CNS inflammation, 247
Tricyclic antidepressants as adjunct analgesics, 83
Thermography and neuropharmacology, 169
Turner R & Jones T: Techniques for imaging neuroscience, 3–20

Ultrasound and neuropharmacology, 169

Vasculitis and activated microglia, 128, 129
Ventrolateral prefrontal cortex (VLPFC), 52–54

Video-EEG telemetry, 182
Volumetric and other morphometric procedures, 63–64
Voxel-based morphometry (VBM), 64, 161, 209, 213
Wada test, 186, 188–190
Weinberger DR *see* **Hariri AR**
Wernicke-Korsakoff syndrome, 63
Williams TM *see* **Lingford-Hughes AR**
Wise RJS: Language systems in normal and aphasic human subjects: functional imaging studies and inferences from animal studies, 95–119